Market News AIOpen the app

CAI stock news · Caris Life Sciences

Stories about Caris Life Sciences (CAI) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CAI

Follow Caris Life Sciences (CAI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CAI
Free on the App Store and Google Play, or on the web.
  1. Nov 6, 2026, 6:07 PM ET · Opinion

    Citigroup increased its price target for Caris Life Sciences from $28.00 to $36.00 and still rates it a Buy.

    Good for CAI

    Citigroup raised its Caris price target from $28.00 to $36.00 and kept its Buy rating. The more favorable analyst view is positive for CAI, though no new company results were reported.

  2. Sep 14, 2026, 4:46 PM ET · Market

    Caris Life Sciences, Inc. says it will present at the Morgan Stanley Global Healthcare Conference on September 14, 2026.

    Neutral

    Caris said it will present at the Morgan Stanley healthcare conference and will post the presentation online; this routine administrative filing does not change the company view.